文献速递肿瘤 PET/CT核素与放射性配体治疗

雄激素阻断对复发或转移性涎腺导管癌患者[68Ga]Ga-PSMA-11与[18F]FDG PET摄取的影响:一项前瞻性影像研究

The effect of androgen blockade on [68Ga]Ga-PSMA-11 and [18F]FDG PET uptake in patients with recurrent or metastatic salivary duct carcinoma: a prospective imaging study.
PubMed 文献 · EJNMMI Res · 2025-07-15

前瞻性纳入8例开始联合雄激素阻断(戈舍瑞林联合比卡鲁胺)作为标准治疗的复发和/或转移性雄激素受体阳性涎腺导管癌患者,在联合雄激素阻断开始前21天内及开始后21±7天行[68Ga]Ga-PSMA-11与[18F]FDG PET/CT。共分析80个转移灶,PSMA SUVmax总体无显著变化(p=0.74),FDG SUVmax总体中位显著升高+0.97(p<0.001)。

要点

  • 联合雄激素阻断三周后肿瘤PSMA摄取未显著升高(Wilcoxon符号秩检验p=0.74)。
  • 联合雄激素阻断三周后肿瘤FDG摄取显著升高,中位升高+0.97(p<0.001)。
  • 中位无进展生存期为2.2个月(95%CI 1.7-2.7个月)。

核心结论

  • 复发和/或转移性涎腺导管癌患者接受雄激素阻断三周后,肿瘤PSMA摄取未出现显著升高。
  • 相反,联合雄激素阻断三周后肿瘤FDG摄取显著升高,可能反映该队列肿瘤反应差和/或一过性治疗相关效应。

研究设计与样本

  • 前瞻性纳入8例开始联合雄激素阻断(戈舍瑞林联合比卡鲁胺)作为标准治疗的复发和/或转移性雄激素受体阳性涎腺导管癌患者。
  • 在联合雄激素阻断开始前21天内及开始后21±7天行[68Ga]Ga-PSMA-11与[18F]FDG PET/CT扫描。
  • 按病灶分析共80个转移灶,获取PSMA与FDG阳性病灶的SUVmax等PET参数。
  • 临床试验注册号NCT04214353,注册日期2019年12月13日。

主要发现

  • PSMA SUVmax在20个病灶(25%)升高、46个病灶(58%)稳定、14个病灶(18%)降低,总体无显著变化(Wilcoxon符号秩检验p=0.74)。
  • FDG SUVmax在35个病灶(44%)升高、39个病灶(49%)稳定、6个病灶(8%)降低,总体中位显著升高+0.97(Wilcoxon符号秩检验p<0.001)。
  • SUVmax变化分类为升高(≥+20%)、稳定(-20%至+20%之间)或降低(≤-20%)。
  • 中位无进展生存期为2.2个月(95%CI 1.7-2.7个月)。

关键数值与推荐

  • SUVmax变化分类:升高为≥+20%,稳定为-20%至+20%之间,降低为≤-20%。
  • PSMA SUVmax总体变化无统计学显著性(p=0.74)。
  • FDG SUVmax总体中位升高+0.97,有统计学显著性(p<0.001)。
  • 中位无进展生存期2.2个月(95%CI 1.7-2.7个月)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The expression of prostate-specific membrane antigen (PSMA), a target for oncological imaging and treatment, is upregulated by androgen blockade in prostate cancer. Salivary duct carcinoma (SDC), an aggressive histological subtype of salivary gland cancer, resembles prostate cancer in terms of PSMA and androgen receptor (AR) expression. A similar upregulation of PSMA in SDC would have implications for future studies with PSMA-targeted imaging and therapy. Additionally, FDG PET/CT scans are frequently used for SDC imaging, but the effect of androgen blockade on FDG uptake is unknown. This study investigated the effect of combined androgen blockade (CAB) on tumour PSMA and FDG uptake in patients with SDC. RESULTS: Eight patients with recurrent and/or metastatic AR-positive SDC who started CAB (goserelin plus bicalutamide) as standard of care were prospectively enrolled. [68 Ga]Ga-PSMA-11 and [18F]FDG PET/CT scans were performed within 21 days before and 21 ± 7 days after CAB initiation. PET parameters, including SUVmax, were obtained for PSMA and FDG positive lesions. A total of 80 metastatic lesions were analysed on a per-lesion basis. SUVmax changes after CAB initiation were categorised as increased (≥ + 20%), stable (between -20% and + 20%), or decreased (≤ -20%). The PSMA SUVmax increased in 20 lesions (25%), remained stable in 46 lesions (58%), and decreased in 14 lesions (18%), with no significant overall change (Wilcoxon signed rank test, p = 0.74). The FDG SUVmax increased in 35 lesions (44%), remained stable in 39 lesions (49%), and decreased in 6 lesions (8%), with a significant overall median increase of + 0.97 (Wilcoxon signed rank test, p < 0.001). The median PFS was 2.2 months (95% confidence interval 1.7-2.7 months). CONCLUSIONS: Androgen blockade in patients with recurrent and/or metastatic SDC did not induce a significant increase in tumour PSMA uptake after three weeks. In contrast, tumour FDG uptake increased significantly after three weeks of CAB, which may reflect the poor tumour response in this cohort and/or a transient treatment-related effect. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04214353. Registered 13 December 2019.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. van Ruitenbeek NJ, Uijen MJM, Driessen CML, et al. The effect of androgen blockade on [68Ga]Ga-PSMA-11 and [18F]FDG PET uptake in patients with recurrent or metastatic salivary duct carcinoma: a prospective imaging study. EJNMMI Res. 2025. PMID: 40663212. doi:10.1186/s13550-025-01275-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。